Advanced search
Publication Cover
Leukemia & Lymphoma Volume 56, 2015 - Issue 5
Submit an article Journal homepage
5,035
Views
93
CrossRef citations to date
0
Altmetric
Original Article: Clinical

A Phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia

Simon Z. HeDepartment of Clinical Haematology and BMT Service, The Royal Melbourne Hospital, Melbourne, Australia;Department of Medicine at The Royal Melbourne Hospital, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Australia;The Walter and Eliza Hall Institute of Medical Research, Melbourne, AustraliaCorrespondence[email protected]
,
Samantha BusfieldCSL Research and Development, Melbourne, Australia
,
David S. RitchieDepartment of Clinical Haematology and BMT Service, The Royal Melbourne Hospital, Melbourne, Australia;Department of Medicine at The Royal Melbourne Hospital, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Australia;Peter MacCallum Cancer Centre, Melbourne, Australia;Victorian Comprehensive Cancer Centre, Melbourne, Australia
,
Mark S. HertzbergWestmead Hospital, Sydney, Australia;Prince of Wales Hospital, Sydney, Australia
,
Simon DurrantRoyal Brisbane and Women's Hospital, Brisbane, Australia
,
Ian D. LewisRoyal Adelaide Hospital, Adelaide, Australia
,
Paula MarltonPrincess Alexandra Hospital, Brisbane, Australia;University of Queensland School of Medicine, Queensland, Australia
,
Andrew J. McLachlanFaculty of Pharmacy and Centre for Education and Research on Ageing, University of Sydney and Concord Hospital, Sydney, Australia
,
Ian KerridgeWestmead Hospital, Sydney, Australia
,
Kenneth F. BradstockWestmead Hospital, Sydney, Australia
,
Glen KennedyRoyal Brisbane and Women's Hospital, Brisbane, Australia
,
Andrew W. BoydRoyal Brisbane and Women's Hospital, Brisbane, Australia;University of Queensland School of Medicine, Queensland, Australia;QIMR Berghofer Medical Research Institute, Queensland, Australia
,
Trina M. YeadonQIMR Berghofer Medical Research Institute, Queensland, Australia
,
Angel F. LopezCentre for Cancer Biology, University of South Australia, Adelaide, Australia
,
Hayley S. RamshawCentre for Cancer Biology, University of South Australia, Adelaide, Australia
,
Harry IlandRoyal Prince Alfred Hospital, Sydney, Australia
,
Simone BamfordCSL Research and Development, Melbourne, Australia
,
Megan BarndenCSL Research and Development, Melbourne, Australia
,
Mark DeWitteCSL Research and Development, Melbourne, Australia
,
Russell BasserCSL Research and Development, Melbourne, Australia
&
Andrew W. RobertsDepartment of Clinical Haematology and BMT Service, The Royal Melbourne Hospital, Melbourne, Australia;Department of Medicine at The Royal Melbourne Hospital, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Australia;The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia;Victorian Comprehensive Cancer Centre, Melbourne, Australia
 show all
Pages 1406-1415 | Received 05 Jun 2014, Accepted 12 Aug 2014, Published online: 20 Nov 2014

Citations (93)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (5)

Giulia Ciotti, Giovanni Marconi, Alessandra Sperotto, Maria B Giannini, Michele Gottardi & Giovanni Martinelli. (2023) Biological therapy in elderly patients with acute myeloid leukemia. Expert Opinion on Biological Therapy 23:2, pages 175-194.
Read now
Hélène Bonnevaux, Stephane Guerif, Jana Albrecht, Erwan Jouannot, Thibaud De Gallier, Christian Beil, Christian Lange, Wulf Dirk Leuschner, Marion Schneider, Cendrine Lemoine, Anne Caron, Céline Amara, Cédric Barrière, Justine Siavellis, Valérie Bardet, Ernesto Luna, Pankaj Agrawal, Donald R. Drake, Ercole Rao, Peter Wonerow, Chantal Carrez, Véronique Blanc, Karl Hsu, Dmitri Wiederschain, Paula G. Fraenkel & Angéla Virone-Oddos. (2021) Pre-clinical development of a novel CD3-CD123 bispecific T-cell engager using cross-over dual-variable domain (CODV) format for acute myeloid leukemia (AML) treatment. OncoImmunology 10:1.
Read now
Katherine D. Cummins & Saar Gill. (2018) Anti-CD123 chimeric antigen receptor T-cells (CART): an evolving treatment strategy for hematological malignancies, and a potential ace-in-the-hole against antigen-negative relapse. Leukemia & Lymphoma 59:7, pages 1539-1553.
Read now
Fu-rong Liu, Hui Jin, Yin Wang, Chen Chen, Ming Li, Sheng-jun Mao, Qiantao Wang & Hui Li. (2017) Anti-CD123 antibody-modified niosomes for targeted delivery of daunorubicin against acute myeloid leukemia. Drug Delivery 24:1, pages 882-890.
Read now
Armin Rashidi & Roland B. Walter. (2016) Antigen-specific immunotherapy for acute myeloid leukemia: where are we now, and where do we go from here?. Expert Review of Hematology 9:4, pages 335-350.
Read now

Articles from other publishers (88)

Yan-Ruide Li, Ying Fang, Zibai Lyu, Yichen Zhu & Lili Yang. (2023) Exploring the dynamic interplay between cancer stem cells and the tumor microenvironment: implications for novel therapeutic strategies. Journal of Translational Medicine 21:1.
Crossref
Evan C. Chen & Jacqueline S. Garcia. (2023) Immunotherapy for Acute Myeloid Leukemia: Current Trends, Challenges, and Strategies. Acta Haematologica, pages 1-1.
Crossref
Karina Barbosa & Aniruddha J. Deshpande. (2023) Therapeutic targeting of leukemia stem cells in acute myeloid leukemia. Frontiers in Oncology 13.
Crossref
Máté G. Kiss, John E. Mindur, Abi G. Yates, Donghoon Lee, John F. Fullard, Atsushi Anzai, Wolfram C. Poller, Kathleen A. Christie, Yoshiko Iwamoto, Vladimir Roudko, Jeffrey Downey, Christopher T. Chan, Pacific Huynh, Henrike Janssen, Achilles Ntranos, Jan D. Hoffmann, Walter Jacob, Sukanya Goswami, Sumnima Singh, David Leppert, Jens Kuhle, Seunghee Kim-Schulze, Matthias Nahrendorf, Benjamin P. Kleinstiver, Fay Probert, Panos Roussos, Filip K. Swirski & Cameron S. McAlpine. (2023) Interleukin-3 coordinates glial-peripheral immune crosstalk to incite multiple sclerosis. Immunity 56:7, pages 1502-1514.e8.
Crossref
Ying Chen, Jishi Wang, Fengqi Zhang & Ping Liu. (2023) A perspective of immunotherapy for acute myeloid leukemia: Current advances and challenges. Frontiers in Pharmacology 14.
Crossref
Elvira Pelosi, Germana Castelli & Ugo Testa. (2023) CD123 a Therapeutic Target for Acute Myeloid Leukemia and Blastic Plasmocytoid Dendritic Neoplasm. International Journal of Molecular Sciences 24:3, pages 2718.
Crossref
Laurent Gauthier, Angela Virone-Oddos, Jochen Beninga, Benjamin Rossi, Céline Nicolazzi, Céline Amara, Audrey Blanchard-Alvarez, Nicolas Gourdin, Jacqueline Courta, Alexandra Basset, Magali Agnel, Franceline Guillot, Gwendoline Grondin, Hélène Bonnevaux, Anne-Laure Bauchet, Ariane Morel, Yannis Morel, Marielle Chiron & Eric Vivier. (2023) Control of acute myeloid leukemia by a trifunctional NKp46-CD16a-NK cell engager targeting CD123. Nature Biotechnology.
Crossref
Chen Tian & Zehui Chen. (2023) Immune therapy: a new therapy for acute myeloid leukemia. Blood Science 5:1, pages 15-24.
Crossref
Shayan Rahmani, Niloufar Yazdanpanah & Nima Rezaei. (2022) Natural killer cells and acute myeloid leukemia: promises and challenges. Cancer Immunology, Immunotherapy 71:12, pages 2849-2867.
Crossref
Kah Teong Soh, Alexis Conway, Xiaojun Liu & Paul K. Wallace. (2022) Development of a 27‐color panel for the detection of measurable residual disease in patients diagnosed with acute myeloid leukemia. Cytometry Part A 101:11, pages 970-983.
Crossref
Basil Al-Kaabneh, Benjamin Frisch & Omar S. Aljitawi. (2022) The Potential Role of 3D In Vitro Acute Myeloid Leukemia Culture Models in Understanding Drug Resistance in Leukemia Stem Cells. Cancers 14:21, pages 5252.
Crossref
Shilin Xu, Meichen Zhang, Xiaocui Fang, Xuechun Hu, Haiyan Xing, Yanlian Yang, Jie Meng, Tao Wen, Jian Liu, Jianxiang Wang, Chen Wang & Haiyan Xu. (2022) CD123 Antagonistic Peptides Assembled with Nanomicelles Act as Monotherapeutics to Combat Refractory Acute Myeloid Leukemia. ACS Applied Materials & Interfaces 14:34, pages 38584-38593.
Crossref
Sophia K. Khaldoyanidi, Antreas Hindoyan, Anthony Stein & Marion Subklewe. (2022) Leukemic stem cells as a target for eliminating acute myeloid leukemia: Gaps in translational research. Critical Reviews in Oncology/Hematology 175, pages 103710.
Crossref
Elodie Bôle-Richard, Naveen Pemmaraju, Blandine Caël, Etienne Daguindau & Andrew A. Lane. (2022) CD123 and More: How to Target the Cell Surface of Blastic Plasmacytoid Dendritic Cell Neoplasm. Cancers 14:9, pages 2287.
Crossref
Kieran D. Sahasrabudhe, Audrey M. Sigmund & Bhavana Bhatnagar. 2022. Handbook of Cancer and Immunology. Handbook of Cancer and Immunology 1 41 .
Anna Aureli, Beatrice Marziani, Tommaso Sconocchia, Maria Ilaria Del Principe, Elisa Buzzatti, Gianmario Pasqualone, Adriano Venditti & Giuseppe Sconocchia. (2021) Immunotherapy as a Turning Point in the Treatment of Acute Myeloid Leukemia. Cancers 13:24, pages 6246.
Crossref
Faroogh Marofi, Heshu Sulaiman Rahman, Zaid Mahdi Jaber Al-Obaidi, Abduladheem Turki Jalil, Walid Kamal Abdelbasset, Wanich Suksatan, Aleksei Evgenievich Dorofeev, Navid Shomali, Max Stanley Chartrand, Yashwant Pathak, Ali Hassanzadeh, Behzad Baradaran, Majid Ahmadi, Hossein Saeedi, Safa Tahmasebi & Mostafa Jarahian. (2021) Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients. Stem Cell Research & Therapy 12:1.
Crossref
Ilias Christodoulou, Won Jin Ho, Andrew Marple, Jonas W Ravich, Ada Tam, Ruyan Rahnama, Adam Fearnow, Cambrynne Rietberg, Sean Yanik, Elena E Solomou, Ravi Varadhan, Michael A Koldobskiy & Challice L Bonifant. (2021) Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities. Journal for ImmunoTherapy of Cancer 9:12, pages e003894.
Crossref
Alessandro Isidori, Claudio Cerchione, Naval Daver, Courtney DiNardo, Guillermo Garcia-Manero, Marina Konopleva, Elias Jabbour, Farhad Ravandi, Tapan Kadia, Adolfo de la Fuente Burguera, Alessandra Romano, Federica Loscocco, Giuseppe Visani, Giovanni Martinelli, Hagop Kantarjian & Antonio Curti. (2021) Immunotherapy in Acute Myeloid Leukemia: Where We Stand. Frontiers in Oncology 11.
Crossref
Stephanie Sendker, Dirk Reinhardt & Naghmeh Niktoreh. (2021) Redirecting the Immune Microenvironment in Acute Myeloid Leukemia. Cancers 13:6, pages 1423.
Crossref
Lok Lam Ngai, Angèle Kelder, Jeroen J. W. M. Janssen, Gert J. Ossenkoppele & Jacqueline Cloos. (2021) MRD Tailored Therapy in AML: What We Have Learned So Far. Frontiers in Oncology 10.
Crossref
. (2020) Treatment of Acute Myeloid Leukemia: A Concise Overview. Abasyn Journal Life Sciences, pages 111-128.
Crossref
Jenna L. Carter, Katie Hege, Jay Yang, Hasini A. Kalpage, Yongwei Su, Holly Edwards, Maik Hüttemann, Jeffrey W. Taub & Yubin Ge. (2020) Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy. Signal Transduction and Targeted Therapy 5:1.
Crossref
Khaja Syed, Sara Naguib, Zhao-Jun Liu, Luisa Cimmino & Feng-Chun Yang. (2020) Novel combinations to improve hematopoiesis in myelodysplastic syndrome. Stem Cell Research & Therapy 11:1.
Crossref
Jing Xu & Ting Niu. (2020) Natural killer cell-based immunotherapy for acute myeloid leukemia. Journal of Hematology & Oncology 13:1.
Crossref
Breann Yanagisawa, Brandy Perkins, Theodoros Karantanos, Mark Levis, Gabriel Ghiaur, B. Douglas Smith & Richard J. Jones. (2020) Expression of putative leukemia stem cell targets in genetically-defined acute myeloid leukemia subtypes. Leukemia Research 99, pages 106477.
Crossref
Michael J. Slade & Geoffrey L. Uy. (2020) CD123 bi-specific antibodies in development in AML: What do we know so far?. Best Practice & Research Clinical Haematology 33:4, pages 101219.
Crossref
Wei Shi, Weiwei Jin, Linghui Xia & Yu Hu. (2020) Novel agents targeting leukemia cells and immune microenvironment for prevention and treatment of relapse of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. Acta Pharmaceutica Sinica B 10:11, pages 2125-2139.
Crossref
Peter Valent, Karin Bauer, Irina Sadovnik, Dubravka Smiljkovic, Daniel Ivanov, Harald Herrmann, Yüksel Filik, Gregor Eisenwort, Wolfgang R. Sperr & Werner Rabitsch. (2020) Cell-based and antibody-mediated immunotherapies directed against leukemic stem cells in acute myeloid leukemia: Perspectives and open issues. Stem Cells Translational Medicine 9:11, pages 1331-1343.
Crossref
Hanadi El Achi, Edouard Dupont, Shilpa Paul & Joseph D. Khoury. (2020) CD123 as a Biomarker in Hematolymphoid Malignancies: Principles of Detection and Targeted Therapies. Cancers 12:11, pages 3087.
Crossref
Tatiana Lopatina, Cristina Grange, Claudia Cavallari, Victor Navarro-Tableros, Giusy Lombardo, Arturo Rosso, Massimo Cedrino, Margherita Alba Carlotta Pomatto, Malvina Koni, Francesca Veneziano, Isabella Castellano, Giovanni Camussi & Maria Felice Brizzi. (2020) Targeting IL-3Rα on tumor-derived endothelial cells blunts metastatic spread of triple-negative breast cancer via extracellular vesicle reprogramming. Oncogenesis 9:10.
Crossref
Y. B. Balzhanova & V. G. Savchenko. (2020) The role of interleukin-3 and its receptor in acute leukemia pathogenesis. Russian journal of hematology and transfusiology 65:3, pages 335-350.
Crossref
Lia Walcher, Ann-Kathrin Kistenmacher, Huizhen Suo, Reni Kitte, Sarah Dluczek, Alexander Strauß, André-René Blaudszun, Tetyana Yevsa, Stephan Fricke & Uta Kossatz-Boehlert. (2020) Cancer Stem Cells—Origins and Biomarkers: Perspectives for Targeted Personalized Therapies. Frontiers in Immunology 11.
Crossref
Kenichi Miyamoto & Yosuke Minami. (2020) Cutting Edge Molecular Therapy for Acute Myeloid Leukemia. International Journal of Molecular Sciences 21:14, pages 5114.
Crossref
James T. Oswald, Haritosh Patel, Daid Khan, Ninweh N. Jeorje, Hossein Golzar, Erin L. Oswald & Shirley Tang. (2020) Drug Delivery Systems Using Surface Markers for Targeting Cancer Stem Cells. Current Pharmaceutical Design 26:17, pages 2057-2071.
Crossref
Matteo Libero Baroni, Diego Sanchez Martinez, Francisco Gutierrez Aguera, Heleia Roca Ho, Maria Castella, Samanta Zanetti, Talia Velasco Hernandez, Rafael Diaz de la Guardia, Julio Castaño, Eduardo Anguita, Susana Vives, Josep Nomdedeu, Helene Lapillone, Anne E Bras, Vincent H J van der Velden, Jordi Junca, Pedro Marin, Alex Bataller, Jordi Esteve, Binje Vick, Irmela Jeremias, Angel Lopez, Marc Sorigue, Clara Bueno & Pablo Menendez. (2020) 41BB-based and CD28-based CD123-redirected T-cells ablate human normal hematopoiesis in vivo. Journal for ImmunoTherapy of Cancer 8:1, pages e000845.
Crossref
Mayumi Sugita & Monica L. Guzman. (2020) CD123 as a Therapeutic Target Against Malignant Stem Cells. Hematology/Oncology Clinics of North America 34:3, pages 553-564.
Crossref
Cole Sterling & Jonathan Webster. (2020) Harnessing the immune system after allogeneic stem cell transplant in acute myeloid leukemia. American Journal of Hematology 95:5, pages 529-547.
Crossref
Rowa Y. Alhabbab. (2020) Targeting Cancer Stem Cells by Genetically Engineered Chimeric Antigen Receptor T Cells. Frontiers in Genetics 11.
Crossref
Anne Bordron, Cristina Bagacean, Adrian Tempescul, Christian Berthou, Eléonore Bettacchioli, Sophie Hillion & Yves Renaudineau. (2019) Complement System: a Neglected Pathway in Immunotherapy. Clinical Reviews in Allergy & Immunology 58:2, pages 155-171.
Crossref
Liqun Yang, Pengfei Shi, Gaichao Zhao, Jie Xu, Wen Peng, Jiayi Zhang, Guanghui Zhang, Xiaowen Wang, Zhen Dong, Fei Chen & Hongjuan Cui. (2020) Targeting cancer stem cell pathways for cancer therapy. Signal Transduction and Targeted Therapy 5:1.
Crossref
Adam J. LambleSarah K. Tasian. (2019) Opportunities for immunotherapy in childhood acute myeloid leukemia. Hematology 2019:1, pages 218-225.
Crossref
Mehrdad Mahalleh, Mahsima Shabani, Elham Rayzan & Nima Rezaei. (2019) Reinforcing the primary immunotherapy modulators against acute leukemia; monoclonal antibodies in AML. Immunotherapy 11:18, pages 1583-1600.
Crossref
Adam J. LambleSarah K. Tasian. (2019) Opportunities for immunotherapy in childhood acute myeloid leukemia. Blood Advances 3:22, pages 3750-3758.
Crossref
Mingyue Shi, Ruijun J. Su, Kamal-Preet Parmar, Rahman Chaudhry, Kai Sun, Jianyu Rao & Mingyi Chen. (2019) CD123: A Novel Biomarker for Diagnosis and Treatment of Leukemia. Cardiovascular & Hematological Disorders-Drug Targets 19:3, pages 195-204.
Crossref
Gaëlle H. Martin, Nainita Roy, Sohini Chakraborty, Alexis Desrichard, Stephen S. Chung, Carolien M. Woolthuis, Wenhuo Hu, Iryna Berezniuk, Francine E. Garrett-Bakelman, Jörg Hamann, Sean M. Devlin, Timothy A. Chan & Christopher Y. Park. (2019) CD97 is a critical regulator of acute myeloid leukemia stem cell function. Journal of Experimental Medicine 216:10, pages 2362-2377.
Crossref
Yufeng Shang & Fuling Zhou. (2019) Current Advances in Immunotherapy for Acute Leukemia: An Overview of Antibody, Chimeric Antigen Receptor, Immune Checkpoint, and Natural Killer. Frontiers in Oncology 9.
Crossref
Testa, Pelosi & Castelli. (2019) CD123 as a Therapeutic Target in the Treatment of Hematological Malignancies. Cancers 11:9, pages 1358.
Crossref
Cornelia Hutmacher, Laura Volta, Francesco Rinaldi, Patrizia Murer, Renier Myburgh, Markus G. Manz & Dario Neri. (2019) Development of a novel fully-human anti-CD123 antibody to target acute myeloid leukemia. Leukemia Research 84, pages 106178.
Crossref
Peter Valent, Irina Sadovnik, Gregor Eisenwort, Karin Bauer, Harald Herrmann, Karoline V. Gleixner, Axel Schulenburg, Werner Rabitsch, Wolfgang R. Sperr & Dominik Wolf. (2019) Immunotherapy-Based Targeting and Elimination of Leukemic Stem Cells in AML and CML. International Journal of Molecular Sciences 20:17, pages 4233.
Crossref
Brent A. Williams, Arjun Law, Judit Hunyadkurti, Stephanie Desilets, Jeffrey V. Leyton & Armand Keating. (2019) Antibody Therapies for Acute Myeloid Leukemia: Unconjugated, Toxin-Conjugated, Radio-Conjugated and Multivalent Formats. Journal of Clinical Medicine 8:8, pages 1261.
Crossref
Linde M. Morsink & Roland B. Walter. (2019) Novel monoclonal antibody-based therapies for acute myeloid leukemia. Best Practice & Research Clinical Haematology 32:2, pages 116-126.
Crossref
Hisham F. Bahmad, Farah Chamaa, Sahar Assi, Reda M. Chalhoub, Tamara Abou-Antoun & Wassim Abou-Kheir. (2019) Cancer Stem Cells in Neuroblastoma: Expanding the Therapeutic Frontier. Frontiers in Molecular Neuroscience 12.
Crossref
Michael Dougan, Glenn Dranoff & Stephanie K. Dougan. (2019) GM-CSF, IL-3, and IL-5 Family of Cytokines: Regulators of Inflammation. Immunity 50:4, pages 796-811.
Crossref
Jens Bauer, Annika Nelde, Tatjana Bilich & Juliane Walz. (2019) Antigen Targets for the Development of Immunotherapies in Leukemia. International Journal of Molecular Sciences 20:6, pages 1397.
Crossref
Yuxin Liu, Jan Philipp Bewersdorf, Maximilian Stahl & Amer M. Zeidan. (2019) Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: The dawn of a new era?. Blood Reviews 34, pages 67-83.
Crossref
Jan W. Gratama. (2019) Issue Highlights – March 2019. Cytometry Part B: Clinical Cytometry 96:2, pages 93-95.
Crossref
Anne E. Bras, Valerie Haas, Arthur Stigt, Mojca Jongen‐Lavrencic, H. Berna Beverloo, Jeroen G. Marvelde, C. Michel Zwaan, Jacques J.M. Dongen, Jeanette H.W. Leusen & Vincent H.J. Velden. (2018) CD123 expression levels in 846 acute leukemia patients based on standardized immunophenotyping. Cytometry Part B: Clinical Cytometry 96:2, pages 134-142.
Crossref
Eric S. Winer & Richard M. Stone. (2019) Novel therapy in Acute myeloid leukemia (AML): moving toward targeted approaches. Therapeutic Advances in Hematology 10, pages 204062071986064.
Crossref
Cristina Maccalli, Sarah K. Tasian & Sergio Rutella. 2019. Cancer Stem Cell Resistance to Targeted Therapy. Cancer Stem Cell Resistance to Targeted Therapy 153 172 .
Amar Desai, Yan Yan & Stanton L. Gerson. (2019) Concise Reviews: Cancer Stem Cell Targeted Therapies: Toward Clinical Success. Stem Cells Translational Medicine 8:1, pages 75-81.
Crossref
Ofrat Beyar-Katz & Saar Gill. (2018) Novel Approaches to Acute Myeloid Leukemia Immunotherapy. Clinical Cancer Research 24:22, pages 5502-5515.
Crossref
Yelena Kovtun, Gregory E. Jones, Sharlene Adams, Lauren Harvey, Charlene A. Audette, Alan Wilhelm, Chen Bai, Lingyun Rui, Rassol Laleau, Fenghua Liu, Olga Ab, Yulius Setiady, Nicholas C. Yoder, Victor S. Goldmacher, Ravi V. J. Chari, Jan Pinkas & Thomas Chittenden. (2018) A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells. Blood Advances 2:8, pages 848-858.
Crossref
Giusy Lombardo, Maddalena Gili, Cristina Grange, Claudia Cavallari, Patrizia Dentelli, Gabriele Togliatto, Daniela Taverna, Giovanni Camussi & Maria Felice Brizzi. (2017) IL-3R-alpha blockade inhibits tumor endothelial cell-derived extracellular vesicle (EV)-mediated vessel formation by targeting the β-catenin pathway. Oncogene 37:9, pages 1175-1191.
Crossref
Sarah Tasian, Martin Bornhäuser & Sergio Rutella. (2018) Targeting Leukemia Stem Cells in the Bone Marrow Niche. Biomedicines 6:1, pages 22.
Crossref
Fu Li, May Kung Sutherland, Changpu Yu, Roland B. Walter, Lori Westendorf, John Valliere-Douglass, Lucy Pan, Ashley Cronkite, Django Sussman, Kerry Klussman, Michelle Ulrich, Martha E. Anderson, Ivan J. Stone, Weiping Zeng, Mechthild Jonas, Timothy S. Lewis, Maitrayee Goswami, Sa A. Wang, Peter D. Senter, Che-Leung Law, Eric J. Feldman & Dennis R. Benjamin. (2018) Characterization of SGN-CD123A, A Potent CD123-Directed Antibody–Drug Conjugate for Acute Myeloid Leukemia. Molecular Cancer Therapeutics 17:2, pages 554-564.
Crossref
Carlos Cuesta-Mateos, Ana Alcaraz-Serna, Beatriz Somovilla-Crespo & Cecilia Muñoz-Calleja. (2018) Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets. Frontiers in Immunology 8.
Crossref
Dan Yang, Xiuqun Zhang, Xuezhong Zhang & Yanli Xu. (2017) The progress and current status of immunotherapy in acute myeloid leukemia. Annals of Hematology 96:12, pages 1965-1982.
Crossref
Marco Ruella, Michael Klichinsky, Saad S. Kenderian, Olga Shestova, Amy Ziober, Daniel O. Kraft, Michael Feldman, Mariusz A. Wasik, Carl H. June & Saar Gill. (2017) Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells. Cancer Discovery 7:10, pages 1154-1167.
Crossref
Maximilian Stahl, Benjamin Y. Lu, Tae Kon Kim & Amer M. Zeidan. (2017) Novel Therapies for Acute Myeloid Leukemia: Are We Finally Breaking the Deadlock?. Targeted Oncology 12:4, pages 413-447.
Crossref
Christina Krupka, Felix S. Lichtenegger, Thomas Köhnke, Jan Bögeholz, Veit Bücklein, Michael Roiss, Torben Altmann, To Uyen Do, Rachel Dusek, Keith Wilson, Arnima Bisht, Jon Terrett, Dee Aud, Esteban Pombo-Villar, Christian Rohlff, Wolfgang Hiddemann & Marion Subklewe. (2017) Targeting CD157 in AML using a novel, Fc-engineered antibody construct. Oncotarget 8:22, pages 35707-35717.
Crossref
John A. Hamilton, Andrew D. Cook & Paul P. Tak. (2016) Anti-colony-stimulating factor therapies for inflammatory and autoimmune diseases. Nature Reviews Drug Discovery 16:1, pages 53-70.
Crossref
Taira Maekawa. 2017. Chemotherapy for Leukemia. Chemotherapy for Leukemia 343 361 .
Lucia Masarova, Hagop Kantarjian, Guillermo Garcia-Mannero, Farhad Ravandi, Padmanee Sharma & Naval Daver. 2017. Immunotherapy. Immunotherapy 73 95 .
Germana Castelli, Elvira Pelosi & Ugo Testa. (2016) Targeted therapies in the treatment of adult acute myeloid leukemias: current status and future perspectives. International Journal of Hematologic Oncology 5:4, pages 143-164.
Crossref
Breann Yanagisawa, Gabriel Ghiaur, B. Douglas Smith & Richard J. Jones. (2016) Translating leukemia stem cells into the clinical setting: Harmonizing the heterogeneity. Experimental Hematology 44:12, pages 1130-1137.
Crossref
Saar Gill. (2016) Chimeric antigen receptor T cell therapy in AML: How close are we?. Best Practice & Research Clinical Haematology 29:4, pages 329-333.
Crossref
Marco Ruella, David M. Barrett, Saad S. Kenderian, Olga Shestova, Ted J. Hofmann, Jessica Perazzelli, Michael Klichinsky, Vania Aikawa, Farzana Nazimuddin, Miroslaw Kozlowski, John Scholler, Simon F. Lacey, Jan J. Melenhorst, Jennifer J.D. Morrissette, David A. Christian, Christopher A. Hunter, Michael Kalos, David L. Porter, Carl H. June, Stephan A. Grupp & Saar Gill. (2016) Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies. Journal of Clinical Investigation 126:10, pages 3814-3826.
Crossref
M Cartellieri, A Feldmann, S Koristka, C Arndt, S Loff, A Ehninger, M von Bonin, E P Bejestani, G Ehninger & M P Bachmann. (2016) Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts. Blood Cancer Journal 6:8, pages e458-e458.
Crossref
Norbert Vey, Jacques Delaunay, Giovanni Martinelli, Walter Fiedler, Emmanuel Raffoux, Thomas Prebet, Carlos Gomez-Roca, Cristina Papayannidis, Maxim Kebenko, Peter Paschka, Randolph Christen, Ernesto Guarin, Ann-Marie Bröske, Monika Baehner, Michael Brewster, Antje-Christine Walz, Francesca Michielin, Valeria Runza, Valerie Meresse & Christian Recher. (2016) Phase I clinical study of RG7356, an anti-CD44 humanized antibody, in patients with acute myeloid leukemia. Oncotarget 7:22, pages 32532-32542.
Crossref
Catherine Gao, Jeffrey V. Leyton, Aaron D. Schimmer, Mark Minden & Raymond M. Reilly. (2016) Auger electron-emitting 111 In-DTPA-NLS-CSL360 radioimmunoconjugates are cytotoxic to human acute myeloid leukemia (AML) cells displaying the CD123 + /CD131 − phenotype of leukemia stem cells. Applied Radiation and Isotopes 110, pages 1-7.
Crossref
Sarah A. BuckleyRoland B. Walter. (2015) Antigen-specific immunotherapies for acute myeloid leukemia. Hematology 2015:1, pages 584-595.
Crossref
Elvira Pelosi, Germana Castelli & Ugo Testa. (2015) Targeting LSCs through membrane antigens selectively or preferentially expressed on these cells. Blood Cells, Molecules, and Diseases 55:4, pages 336-346.
Crossref
Armen Mardiros, Stephen J. Forman & Lihua E. Budde. (2015) T cells expressing CD123 chimeric antigen receptors for treatment of acute myeloid leukemia. Current Opinion in Hematology 22:6, pages 484-488.
Crossref
Helena ÅgerstamChristine KarlssonNils HansenCarl SandénMaria AskmyrSofia von PalffyCarl HögbergMarianne RisslerMark WunderlichGunnar JuliussonJohan RichterKjell SjöströmRavi Bhatia, James C. MulloyMarcus JäråsThoas Fioretos. (2015) Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemia. Proceedings of the National Academy of Sciences 112:34, pages 10786-10791.
Crossref
A Pardanani, T Lasho, D Chen, T K Kimlinger, C Finke, D Zblewski, M M Patnaik, K K Reichard, E Rowinsky, C A Hanson, C Brooks & A Tefferi. (2015) Aberrant expression of CD123 (interleukin-3 receptor-α) on neoplastic mast cells. Leukemia 29:7, pages 1605-1608.
Crossref
Sarah A. Buckley & Roland B. Walter. (2015) Update on Antigen-Specific Immunotherapy of Acute Myeloid Leukemia. Current Hematologic Malignancy Reports 10:2, pages 65-75.
Crossref
Gillian A Horne, Ross Kinstrie & Mhairi Copland. (2015) Novel drug therapies in myeloid leukemia: a patent review. Pharmaceutical Patent Analyst 4:3, pages 187-205.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.